Myeloma Paper of the Day, July 30th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Study of health-related quality of life in Waldenström macroglobulinemia patients with MYD88 mutations on ASPEN trial finds zanubrutinib treatment associated with greater HRQOL improvements (diarrhea, nausea/vomiting) vs. ibrutinib.”
Source: Robert Orlowski/X
Authors: Alessandra Tedeschi, Constantine Tam, Roger Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Ramón Garcia-Sanz, Jorge Castillo, Judith Trotman, Steven Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Chan, Aileen Cohen, Shengnan Chen, and Gisoo Barnes.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.
Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.